세계의 골전이 치료 시장 규모는 2025-2032년의 예측 기간 중 8.40%의 CAGR로 확대하며, 2024년 193억 8,000만 달러에서 2032년에는 369억 4,000만 달러로 성장할 것으로 예측됩니다. 이 시장을 촉진하고 있는 것은 골전이의 리스크를 높이는 암의 전 세계적인 유병률 증가입니다. 방사성 의약품 및 표적 생물제제 등 치료 기술의 발전으로 환자들의 치료 결과가 개선되고 치료 옵션이 확대되고 있습니다. 또한 소아암 환자 증가와 북미의 혁신 주도형 헬스케어 인프라가 시장 성장에 크게 기여하고 있습니다.
2024년 11월, 뼈와 연부조직에 영향을 미치는 전이성 유방암에 대한 국소 투여를 통한 혁신적인 치료법 개발에 전념하는 임상 단계의 비상장 바이오 제약회사 Zetagen Therapeutics, Inc.는 임상 2a상 시험에 첫 환자 2명을 등록했다고 발표했습니다. 이 임상시험은 척수 전이성 용해성 유방암 병변에 대한 ZetaMet(Zeta-BC-003)의 효능을 평가합니다.
세계의 골전이 치료 시장에 대해 조사했으며, 시장의 개요와 유형별, 치료별, 주요 브랜드별, 지역별 동향 및 시장에 참여하는 기업의 개요 등을 제공하고 있습니다.
Global bone metastasis treatment market is projected to witness a CAGR of 8.40% during the forecast period 2025-2032, growing from USD 19.38 billion in 2024 to USD 36.94 billion in 2032. The market is driven by the growing global prevalence of cancer, which increases the risk of bone metastases. Advances in treatment technologies, such as radiopharmaceuticals and targeted biologics, are improving patient outcomes and expanding therapeutic options. Furthermore, rising pediatric cancer cases and North America's innovation-led healthcare infrastructure are contributing significantly to market growth.
For instance, in November 2024, Zetagen Therapeutics, Inc., a private biopharmaceutical company in the clinical stage dedicated to creating innovative therapies through local administration for metastatic breast cancer affecting bone and soft tissues, announced the enrollment of the first two patients in phase 2a study. This study will assess the efficacy of ZetaMet (Zeta-BC-003) in treating spinal metastatic lytic breast cancer lesions.
Rising Global Cancer Burden Fuels Demand for Bone Metastasis Treatment
The increasing prevalence of primary cancers, particularly breast cancer, prostate cancer, and lung cancer, is a significant driver of the bone metastasis treatment market. As these cancers frequently metastasize to bones, the need for early diagnosis and effective treatment of skeletal-related complications is escalating. Advanced imaging modalities and improvements in diagnostics have enabled earlier detection of bone metastases, leading to better therapeutic outcomes. Furthermore, increasing awareness of palliative care and the rising emphasis on quality of life for advanced cancer patients have encouraged the use of bone-targeted therapies such as bisphosphonates and RANK ligand inhibitors. Pharmaceutical companies are also actively investing in innovative drug development to enhance effectiveness and reduce side effects of current treatments. For instance, the American Cancer Society projects that in 2025, there will be approximately 3,770 new cases of primary bone and joint cancers, comprising 2,150 cases in males and 1,620 in females, along with an estimated 2,190 fatalities, including 1,240 in males and 950 in females. This data encompasses both pediatric and adult populations. Primary bone cancers, which originate in the bones, are relatively rare, representing less than 1% of all cancer cases. In adults, cancers that metastasize bones from other sites are significantly more prevalent than primary bone cancers.
Technological Advancements in Targeted Therapies and Radiopharmaceuticals
Ongoing innovations in targeted therapies and radiopharmaceuticals significantly reshape the bone metastasis treatment landscape. Radiopharmaceuticals like Xofigo (radium-223 dichloride) offer more focused approaches, delivering localized radiation therapy that spares healthy tissue and minimizes systemic toxicity. The emergence of combination therapies-pairing bone-targeted agents with immunotherapies or chemotherapy-is enhancing efficacy in managing skeletal metastases. Additionally, artificial intelligence and precision medicine aid in patient stratification and personalized treatment plans, increasing success rates. These advancements not only improve clinical outcomes but also lower the burden of skeletal-related events such as fractures, spinal compression, and pain. Companies are actively launching and refining novel drugs to maintain a competitive advantage. For instance, in March 2023, a team of researchers from the University of Sheffield and the University of East Anglia introduced a novel medication named CADD522 to treat individuals with primary bone cancers. This medication demonstrated a 50% improvement in survival rates in preclinical studies.
Rising Incidences of Bone Metastasis in Pediatric Oncology Accelerates Treatment Needs
Although bone metastasis is more common in adults, its occurrence in pediatric cancers such as neuroblastoma, Ewing sarcoma, and osteosarcoma is growing attention. As pediatric oncology sees rising case detection due to improved diagnostics and awareness, the need for age-specific bone metastasis treatment is becoming critical. Children with metastatic cancer often face rapid disease progression and complications involving bones, demanding early and aggressive intervention. The treatment approach in pediatric cases emphasizes minimizing long-term toxicity while effectively managing skeletal-related complications. Drug developers are now focusing on pediatric clinical trials and safety profiles tailored for children.
North America Maintains Market Leadership
North America dominates the global bone metastasis treatment market due to its high cancer burden, advanced healthcare infrastructure, and strong pharmaceutical R&D ecosystem. The U.S., in particular, reports many cancer cases that often progress to metastatic stages, necessitating robust bone-targeted interventions. Favorable reimbursement policies and fast-track regulatory approvals further facilitate the availability and adoption of advanced therapies. Moreover, patient awareness, widespread access to oncology specialists, and a strong network of cancer treatment centers support proactive treatment. The region is also a hub for clinical trials and drug innovation, contributing significantly to new approvals. The FDA has granted approval for Wyost/Jubbonti (denosumab-bddz; GP2411) in March 2024, marking it as the first biosimilar to the reference drugs Xgeva/Prolia (denosumab) in the United States. This medication will be utilized for the treatment of osteoporosis and hypercalcemia, in addition to preventing skeletal-related events linked to bone metastases from solid tumors.
Future Market Scenario (2025-2032F)
The global bone metastasis treatment market is poised for significant growth driven by the rising global cancer burden and growing awareness of metastatic complications. As cancer survival rates improve due to early diagnosis and advanced treatments, the number of patients at risk for bone metastases is also increasing. Continuous innovations in radiopharmaceuticals, targeted biologics, and minimally invasive surgical techniques enhance treatment efficacy and patient outcomes. Additionally, rising investments in oncology research, increasing use of AI in treatment planning, and growing clinical focus on pediatric metastatic cases are expected to expand market potential. North America will continue to dominate due to high healthcare spending and innovation, while emerging economies in Asia-Pacific are projected to offer substantial opportunities through improved access to oncology care.
Key Players Landscape and Outlook
The key players in the market are significantly investing in the development of bone metastasis treatment and are utilizing strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing large-cap industry players to increase their presence and, therefore, find new opportunities in this market.
For example, in November 2023, Telix proposed an acquisition of Qsam Biosciences for USD 33.1 million, aiming to enhance its product portfolio with a phase 1 radiopharmaceutical for bone cancer. This medication aids in the treatment of cancer that has spread to the bone from various organs, including the breast, lung, and prostate.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.